Piramal Pharma Ltd (PPLPHARMA) Q1 FY27 Earnings Call: EBITDA Margin Expands 400 bps, CDMO Revenue Grows 19% YoY

Piramal Pharma Ltd held its Q1 FY27 earnings call on July 29, 2026. Here's a quick read of what management said — performance, strategy, and the outlook ahead.

Broad-Based Revenue Beat & Margin Inflection

• Rs.2,270 Cr revenue — Q1 FY 2026-2027 grew 17% YoY, with EBITDA surging 72% to Rs.285 Cr and margins expanding ~400 bps to 12.5%.
• CDMO revenue +19% YoY — broad-based growth across India and overseas sites, supported by improved RFP activity and recovery in US biopharma funding.
• Complex hospital generics revenue +17% YoY to Rs.743 Cr — driven by non-US (ROW) markets; management noted Chinese competition but corrective actions initiated over FY 2025-2026 are gaining traction.
• Consumer healthcare mid-teens growth — power brands grew 23% YoY (53% of sales), e-commerce surged 40% YoY (28% of sales), with media spend at 12% of sales.
• Constant currency revenue growth ~9-10% — across all businesses for the quarter, per management's disclosure.
• Customer decision-making timelines remain extended — management flagged geopolitical and trade uncertainties as ongoing headwinds, alongside input cost pressures.

Pipeline Depth, Customer Expansion & Tech Collaborations

• 155 active molecules — including 25 in late-stage/commercial, disclosed annually; management is evaluating whether to increase update frequency.
• Differentiated offerings rose to 40-47% — up from 32% in FY 2025-2026, driven by higher investment in differentiated capacity and customer demand; management expects this share to continue rising over the long-range plan.
• NPS improved to ~60% — as of Q1 FY 2026-2027, up from lower historical levels; a third-party benchmark indicates average CDMO NPS is negative, per management.
• Top 20 CDMO customers growing faster — CEO Peter DeYoung highlighted the "land and expand" strategy, with examples of one project scaling to 5 or 7 molecules over time.
• Collaborations with Ajinomoto Bio-Pharma Services — for ADC technology, and a manufacturing/supply agreement with Botanix for Sofdra; partnership with GenoMoto is a technology collaboration requiring no new investment.
• Later-stage programs have ~50% chance of commercialization — management noted these are typically larger, with potential to become meaningful recurring revenue streams if successful.

Market Share Gains, Tariff Positioning & Channel Mix

• 48% market share in US sevoflurane — maintained in Q1 FY 2026-2027; API and drug product manufactured in Bethlehem, Pennsylvania, with inputs from India.
• Sevoflurane tariff positioning — management stated the company is "reasonably well-positioned" to handle potential US tariff scenarios, including a two-year 0% tariff on India and 100% on generics.
• CHG ex-US growth drove base business — market share gains across the 100-country ROW landscape in Q1 FY 2026-2027, signaling positive momentum for the remainder of FY 2026-2027.
• Canalock supplies expected from Q2 FY 2026-2027 — management cautioned that the organic CHG growth percentage may not persist, with canalog contribution beginning in the current quarter.
• Consumer healthcare power brands at 53% of sales — e-commerce channel contributed 28% of sales, growing 40% YoY; media spend held at 12% of sales.
• Chinese competition remains in CHG — but management's corrective actions, started over FY 2025-2026, are bearing fruit.

Gross Margin Mix, Tax Rate Elevation & EBITDA Path to 25%

• Blended gross margin 64-65% — overseas facilities gross margins range 75-85%, India facilities 55-65%; management cautioned a single quarter is not indicative of the annual profile.
• EBITDA margin target of 25% by FY30 — management targets "company-level EBITDA margins of 25% by FY30", with CDMO (60% of revenue) as the primary driver through improved capacity utilization at overseas facilities.
• Tax rate elevated in FY 2026-2027 — due to higher profit incidence in tax-paying jurisdictions and a disallowance on R&D tax credit at overseas facilities (pending appeal); CFO Vivek Valsaraj guided no sharp reduction in coming quarters.
• Normalized tax rate of 24-25% — expected once overseas operations scale up (period unspecified); management emphasized scaling revenues rather than business reorganization to reduce the tax impact.
• Employee expenses very low single digits YoY — in Q1 FY 2026-2027 (adjusted for forex), reversing the sequential distortion from incentive provisions.
• Other income sustainable run-rate Rs.45-50 Cr — Q1 was elevated due to reversal of provisions no longer required; forex gains can cause significant variation.
• Overseas subsidiaries accumulated losses ~Rs.146 Cr — across 11 subsidiaries as of Q1 FY 2026-2027; management expects increased utilization to drive scale and operating leverage toward break-even.

ADC Facility, Lexington Timeline & $90 Mn Expansion Program

• CAPEX guidance reiterated at $120-135 Mn for FY 2026-2027 — $21 Mn spent in Q1; Lexington CAPEX on track for completion by end of calendar year 2027.
• ADC payload room at Riverview commercialized — revenue potential in the single to low double-digit USD millions range; investment was less than $5 Mn, and the room is immediately available with customer interest expected to benefit FY 2026-2027 and FY 2027-2028.
• $90 Mn expansion program underway — includes the Riverview ADC facility and sterile injectable capacity at Lexington, part of the broader capacity build-out.
• EDC integrated offering expected to gain traction over 3-5 years — Riverview expansion enables larger scale, Lexington commercial expansion allows larger EDC linkages; conjugation at Grangemouth remains the anchor and largest contributor.
• CDMO capacity utilization gap persists — overseas (North America and Europe) facilities are currently underutilized compared to India assets; margin expansion will be driven by improving utilization at these sites.
• Large contract destocking continues — management does not anticipate any sales in FY 2026-2027 from this contract and continues discussions with the innovator; no update on FY 2027-2028 was provided.

Reaffirmed FY27 Outlook, RFP Momentum & Risk Factors

• FY 2026-2027 guidance reaffirmed — management expects sustained revenue growth and margin expansion, incorporating both organic and canalog-related growth; H2 historically sees higher revenues than H1.
• RFP flow increased due to four factors — improved operational performance (reflected in Net Promoter Score), a larger BD team, progress on commercial transformation, and customers having more capital to spend; a specific spike in nearshore interest was noted above the broad-based increase.
• CDMO strategic collaborations signal technology depth — ADC partnership with Ajinomoto Bio-Pharma Services and GenoMoto collaboration build on existing client work without requiring new investments.
• Quality milestone achieved — Sellersville facility (US) received an EIR from US FDA, concluding inspection; the company maintains zero OAI classification across its global network.
• Risks flagged by management — customer decision-making timelines remain extended, geopolitical and trade uncertainties may impact supply chains, and input cost pressures persist.
• Tax loss utilization gradual — significant carry-forward tax losses are available across North American, UK, and European facilities; North American sites are progressing faster than European assets, but management did not commit to a specific timeline for full recognition.